Cargando…

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI

PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated whether polymorphisms of the EGFR gene were associated with clinical outcomes in non-small cell lung cancer (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Minkyu, Cho, Byoung Chul, Lee, Chul Ho, Park, Hyung Soon, Kang, Young Ae, Kim, Se Kyu, Chang, Joon, Kim, Dae Jun, Rha, Sun Young, Kim, Joo Hang, Lee, Ji Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481391/
https://www.ncbi.nlm.nih.gov/pubmed/23074112
http://dx.doi.org/10.3349/ymj.2012.53.6.1128
_version_ 1782247725091258368
author Jung, Minkyu
Cho, Byoung Chul
Lee, Chul Ho
Park, Hyung Soon
Kang, Young Ae
Kim, Se Kyu
Chang, Joon
Kim, Dae Jun
Rha, Sun Young
Kim, Joo Hang
Lee, Ji Hyun
author_facet Jung, Minkyu
Cho, Byoung Chul
Lee, Chul Ho
Park, Hyung Soon
Kang, Young Ae
Kim, Se Kyu
Chang, Joon
Kim, Dae Jun
Rha, Sun Young
Kim, Joo Hang
Lee, Ji Hyun
author_sort Jung, Minkyu
collection PubMed
description PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated whether polymorphisms of the EGFR gene were associated with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with EGFR-TKI. MATERIALS AND METHODS: A polymorphic dinucleotide repeat in intron 1 [CA simple sequence repeat in intron 1(CA-SSR1)] in intron 1 and single nucleotide polymorphisms (SNP-216) in the promoter region of the EGFR gene were evaluated in 71 NSCLC patients by restriction fragment length polymorphism and DNA sequencing. The relationship between genetic polymorphisms and clinical outcomes of treatment with EGFR-TKIs was evaluated. RESULTS: SNP-216G/T polymorphisms were associated with the efficacy of EGFR-TKI. The response rate for the SNP-216G/T tended to be higher than that for G/G (62.5% vs. 27.4%, p=0.057). The SNP-216G/T genotype was also associated with longer progression-free survival compared with the GG genotype (16.7 months vs. 5.1 months, p=0.005). However, the length of CA-SSR1 was not associated with the efficacy of EGFR-TKI. CONCLUSION: SNP-216G/T polymorphism was a potential predictor of clinical outcomes in NSCLC patients treated with EGFR-TKI.
format Online
Article
Text
id pubmed-3481391
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-34813912012-11-01 EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI Jung, Minkyu Cho, Byoung Chul Lee, Chul Ho Park, Hyung Soon Kang, Young Ae Kim, Se Kyu Chang, Joon Kim, Dae Jun Rha, Sun Young Kim, Joo Hang Lee, Ji Hyun Yonsei Med J Original Article PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated whether polymorphisms of the EGFR gene were associated with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with EGFR-TKI. MATERIALS AND METHODS: A polymorphic dinucleotide repeat in intron 1 [CA simple sequence repeat in intron 1(CA-SSR1)] in intron 1 and single nucleotide polymorphisms (SNP-216) in the promoter region of the EGFR gene were evaluated in 71 NSCLC patients by restriction fragment length polymorphism and DNA sequencing. The relationship between genetic polymorphisms and clinical outcomes of treatment with EGFR-TKIs was evaluated. RESULTS: SNP-216G/T polymorphisms were associated with the efficacy of EGFR-TKI. The response rate for the SNP-216G/T tended to be higher than that for G/G (62.5% vs. 27.4%, p=0.057). The SNP-216G/T genotype was also associated with longer progression-free survival compared with the GG genotype (16.7 months vs. 5.1 months, p=0.005). However, the length of CA-SSR1 was not associated with the efficacy of EGFR-TKI. CONCLUSION: SNP-216G/T polymorphism was a potential predictor of clinical outcomes in NSCLC patients treated with EGFR-TKI. Yonsei University College of Medicine 2012-11-01 2012-10-05 /pmc/articles/PMC3481391/ /pubmed/23074112 http://dx.doi.org/10.3349/ymj.2012.53.6.1128 Text en © Copyright: Yonsei University College of Medicine 2012 http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jung, Minkyu
Cho, Byoung Chul
Lee, Chul Ho
Park, Hyung Soon
Kang, Young Ae
Kim, Se Kyu
Chang, Joon
Kim, Dae Jun
Rha, Sun Young
Kim, Joo Hang
Lee, Ji Hyun
EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
title EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
title_full EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
title_fullStr EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
title_full_unstemmed EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
title_short EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
title_sort egfr polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with egfr-tki
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481391/
https://www.ncbi.nlm.nih.gov/pubmed/23074112
http://dx.doi.org/10.3349/ymj.2012.53.6.1128
work_keys_str_mv AT jungminkyu egfrpolymorphismasapredictorofclinicaloutcomeinadvancedlungcancerpatientstreatedwithegfrtki
AT chobyoungchul egfrpolymorphismasapredictorofclinicaloutcomeinadvancedlungcancerpatientstreatedwithegfrtki
AT leechulho egfrpolymorphismasapredictorofclinicaloutcomeinadvancedlungcancerpatientstreatedwithegfrtki
AT parkhyungsoon egfrpolymorphismasapredictorofclinicaloutcomeinadvancedlungcancerpatientstreatedwithegfrtki
AT kangyoungae egfrpolymorphismasapredictorofclinicaloutcomeinadvancedlungcancerpatientstreatedwithegfrtki
AT kimsekyu egfrpolymorphismasapredictorofclinicaloutcomeinadvancedlungcancerpatientstreatedwithegfrtki
AT changjoon egfrpolymorphismasapredictorofclinicaloutcomeinadvancedlungcancerpatientstreatedwithegfrtki
AT kimdaejun egfrpolymorphismasapredictorofclinicaloutcomeinadvancedlungcancerpatientstreatedwithegfrtki
AT rhasunyoung egfrpolymorphismasapredictorofclinicaloutcomeinadvancedlungcancerpatientstreatedwithegfrtki
AT kimjoohang egfrpolymorphismasapredictorofclinicaloutcomeinadvancedlungcancerpatientstreatedwithegfrtki
AT leejihyun egfrpolymorphismasapredictorofclinicaloutcomeinadvancedlungcancerpatientstreatedwithegfrtki